Bionexus Gene Lab Stock Today
| BGLC Stock | USD 5.15 0.05 0.98% |
PerformanceOK
| Odds Of DistressLow
|
BioNexus Gene is trading at 5.15 as of the 24th of July 2025, a 0.98 percent up since the beginning of the trading day. The stock's open price was 5.1. BioNexus Gene has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain Materials | IPO Date 16th of September 2020 | Category Basic Materials |
BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. The company has 1.8 M outstanding shares of which 8.25 K shares are currently shorted by private and institutional investors with about 0.11 trading days to cover. More on BioNexus Gene Lab
Moving together with BioNexus Stock
| 0.65 | DD | Dupont De Nemours Earnings Call This Week | PairCorr |
Moving against BioNexus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioNexus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CEO | SuLeng Tan | ||||
| Business Concentration | Specialty Chemicals, Basic Materials, NASDAQ Composite, Materials, Chemicals, Diagnostics & Research, Healthcare (View all Sectors) | ||||
BioNexus Gene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioNexus Gene's financial leverage. It provides some insight into what part of BioNexus Gene's total assets is financed by creditors.
| |||||
BioNexus Gene Lab (BGLC) is traded on NASDAQ Exchange in USA. It is located in Menara UOA Bangsar, Kuala Lumpur, Malaysia, 59000 and employs 30 people. BioNexus Gene is listed under Specialty Chemicals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.16 M. BioNexus Gene Lab conducts business under Chemicals sector and is part of Materials industry. The entity has 1.8 M outstanding shares of which 8.25 K shares are currently shorted by private and institutional investors with about 0.11 trading days to cover.
BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check BioNexus Gene Probability Of Bankruptcy
Ownership AllocationBioNexus Gene Lab retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check BioNexus Ownership Details
BioNexus Gene Historical Income Statement
BioNexus Stock Against Markets
BioNexus Gene Corporate Management
| Set Chong | Chief Officer | Profile | |
| Sook Yeoh | CEO Director | Profile | |
| Kwan Chan | Marketing Manager | Profile | |
| Too Tham | Managing Director | Profile | |
| Wei Leong | CFO Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.